Literature DB >> 19179066

Down-regulation of K-ras and H-ras in human brain gliomas.

Rena Lymbouridou1, Giannoula Soufla1, Anthoula M Chatzinikola1, Antonios Vakis2, Demetrios A Spandidos3.   

Abstract

Ras genes, a class of nucleotide-binding proteins that regulate normal and transformed cell growth, have been scarcely investigated in human brain tumours. We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens. K-, H- and N-ras transcript levels were determined by real-time RT-PCR and mutational status by PCR-restriction fragment length polymorphism (RFLP) and direct sequencing. p21 protein was evaluated by Western blot analysis. Two K-ras mutations were found in codons 16 and 26 in one pathological and one normal sample, respectively. Glioblastoma multiforme cases exhibited significantly lower K- and H-ras mRNA levels compared to controls (P < 10(-4)). K- and H-ras mRNA down-regulation was not associated with patient outcome or survival. K-ras was positively correlated with H-ras in glioblastomas (P = 0.005), but not in normal specimens. p21 protein was absent in all samples. Our findings provide evidence of K- and H-ras involvement in brain malignant transformation through transcriptional down-regulation, while N-ras seems to contribute less to brain carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19179066     DOI: 10.1016/j.ejca.2008.12.028

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  RRP22: a novel neural tumor suppressor for astrocytoma.

Authors:  Ruokun Chen; Liang Yang; Jiasheng Fang; Lei Huo; Mingyu Zhang; Fenghua Chen; Jinfang Liu; Jun Wu; Yanjin Wang
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

2.  Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Authors:  Benedikte Hasselbalch; Ulrik Lassen; Steinbjørn Hansen; Mats Holmberg; Morten Sørensen; Michael Kosteljanetz; Helle Broholm; Marie-Thérése Stockhausen; Hans Skovgaard Poulsen
Journal:  Neuro Oncol       Date:  2010-02-05       Impact factor: 12.300

3.  K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.

Authors:  Efterpi Dalpa; Victor Gourvas; Nikolaos Soulitzis; Demetrios A Spandidos
Journal:  Med Oncol       Date:  2016-12-09       Impact factor: 3.064

Review 4.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.

Authors:  Hui-Wen Lo
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

5.  Inhibition of glioma by adenovirus KGHV500 encoding anti-p21Ras scFv and carried by cytokine-induced killer cells.

Authors:  Jing Qian; Mo Yang; Qiang Feng; Xin-Yan Pan; Li-Lin Yang; Ju-Lun Yang
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-03

6.  Application of the antitussive agents oxelaidin and butamirate as anti-glioma agents.

Authors:  Sook-Ja Lee; Seon-Yong Yeom; Jee-Young Lee; Chaehwa Park
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

7.  Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels.

Authors:  Inês Crespo; Hermínio Tão; Ana Belen Nieto; Olinda Rebelo; Patrícia Domingues; Ana Luísa Vital; Maria del Carmen Patino; Marcos Barbosa; Maria Celeste Lopes; Catarina Resende Oliveira; Alberto Orfao; María Dolores Tabernero
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

8.  Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.

Authors:  Nicola V L Serão; Kristin R Delfino; Bruce R Southey; Jonathan E Beever; Sandra L Rodriguez-Zas
Journal:  BMC Med Genomics       Date:  2011-06-07       Impact factor: 3.063

9.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival.

Authors:  Ahmed Sadeque; Nicola Vl Serão; Bruce R Southey; Kristin R Delfino; Sandra L Rodriguez-Zas
Journal:  BMC Med Genomics       Date:  2012-12-04       Impact factor: 3.063

10.  SMARCB1 Gene Mutation Predisposes to Earlier Development of Glioblastoma: A Case Report of Familial GBM.

Authors:  Sanjib Mukherjee; Edana Stroberg; Fengfei Wang; Linden Morales; Yuan Shan; Arundhati Rao; Jason H Huang; Erxi Wu; Ekokobe Fonkem
Journal:  J Neuropathol Exp Neurol       Date:  2020-05-01       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.